SCHEMBL17124273

SCHEMBL17124273

COC(=O)[C@@H]1CC[C@]2(C)CC[C@]3(C)C(CCC4[C@@]5(C)CC[C@H](O)C(C)(C)C5CC[C@]43C)C12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 6/20 0.72
TOP2A P11388 2/20 0.72
CES2 O00748 1/20 0.72
CES1 P23141 1/20 0.72
GPBAR1 Q8TDU6 4/20 0.62
PTGES O14684 1/20 0.60
EGLN2 Q96KS0 1/20 0.58
EGLN1 Q9GZT9 1/20 0.58
EGLN3 Q9H6Z9 1/20 0.58
P4HTM Q9NXG6 1/20 0.58
RORC P51449 3/20 0.57
ALB P02768 2/20 0.57
USP2 O75604 2/20 0.57
LMNA P02545 2/20 0.57
HIF1A Q16665 2/20 0.57
NT5E P21589 2/20 0.57
AKR1B10 O60218 1/20 0.57
POLB P06746 1/20 0.57
GLI1 P08151 1/20 0.57
AKR1B1 P15121 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14086956 0.90 PTPN1 (0.80) PTPN1TOP2ACES2CES1GPBAR1
SCHEMBL17124228 0.89 PTPN1 (0.57) PTPN1TOP2ACES2CES1GPBAR1
SCHEMBL17124257 0.88 PTPN1 (0.76) PTPN1TOP2ACES2CES1GPBAR1
SCHEMBL15713700 0.87 GPBAR1 (0.70) PTPN1TOP2AGPBAR1EGLN2EGLN1
SCHEMBL17124247 0.85 PTPN1 (0.72) PTPN1TOP2ACES2CES1GPBAR1
Lupeol SCHEMBL17036708 0.84 PTPN1 (1.00) PTPN1TOP2ACES2CES1GPBAR1
Lupeol SCHEMBL561024 0.84 PTPN1 (1.00) PTPN1TOP2ACES2CES1GPBAR1
Lupeol SCHEMBL21847985 0.84 PTPN1 (1.00) PTPN1TOP2ACES2CES1GPBAR1
Lupeol SCHEMBL21927816 0.84 PTPN1 (1.00) PTPN1TOP2ACES2CES1GPBAR1
Lupeol SCHEMBL148518 0.84 PTPN1 (1.00) PTPN1TOP2ACES2CES1GPBAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150272922-A1 Compounds for Reducing Glucocorticoids, and Methods of Treatment Thereof BIONICHE ANIMAL HEALTH USA, INC. 2015-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150272922-A1 Compounds for Reducing Glucocorticoids, and Methods of Treatment Thereof NR3C1, NR5A1, NR3C2 PTPN1 855/4885TOP2A 982/4885CES2 2448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.